<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04397107</url>
  </required_header>
  <id_info>
    <org_study_id>20K013-001</org_study_id>
    <nct_id>NCT04397107</nct_id>
  </id_info>
  <brief_title>The Therapeutic Value and Mechanism of Recombinant Human Interleukin-2 on Children With Rheumatic Diseases</brief_title>
  <acronym>SLE，pSS，JIA</acronym>
  <official_title>The Therapeutic Value and Mechanism of Recombinant Human Interleukin-2 on Children With Rheumatic Diseases (Systemic Lupus Erythematosus, Primary Sjögren Syndrome, Juvenile Idiopathic Arthritis)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>First Hospital of Jilin University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>First Hospital of Jilin University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study aims to explore the therapeutic value and mechanism of Interleukin-2 on children
      with rheumatic diseases (Systemic Lupus Erythematosus, Primary Sjögren Syndrome, Juvenile
      Idiopathic Arthritis).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators designed a single center, open-label, prospective study that routinely
      administered low-dose IL-2 therapy to monitor the improvement of clinical and laboratory
      parameters to explore its efficacy and to observe changes in immune cell subsets and
      cytokines.

      Methods: Patients were divided into two groups. One received standard therapy, while another
      one administrate with low-does IL-2 plus standard therapy.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 15, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>One group patients were treated with IL-2 and another group patients were treated with routine therapy.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in steroid dose and immunosuppressor dose at 1 year compared to control group</measure>
    <time_frame>1 year</time_frame>
    <description>The average daily doses of steroid and immunosuppressor per square meter was recorded</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Immunologic Impact of IL-2 Treatment</measure>
    <time_frame>1 month,3 month,6 month,1 year</time_frame>
    <description>Laboratory measures were detected, including, C3, C4 and anti-dsDNA titres.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunological Responses</measure>
    <time_frame>1 month,3 month,6 month,1 year</time_frame>
    <description>Enumeration of the number of subjects with a change in the absolute number of immune cells and serum cytokines in the peripheral blood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in SELENA SLEDAI Score</measure>
    <time_frame>1 month,3 month,6 month,1 year</time_frame>
    <description>Assessment version of the SLE Disease Activity Index (SELENA-SLEDAI) change. The higher the score represent the worse of the disease. The total score ranges from 0 to 105 points.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in EULAR SS disease activity index</measure>
    <time_frame>1 month,3 month,6 month,1 year</time_frame>
    <description>Low-activity (ESSDAI&lt;5),moderate-activity (5≤ESSDAI≤13) ,high-activity (ESSDAI≥14) levels.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse drug reactions</measure>
    <time_frame>up to 1 year</time_frame>
    <description>Adverse events includes injection site reactions, influenza-like symptoms, infection, fever, tumor, cardiovascular event，drug-induced liver and kidney damage.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">46</enrollment>
  <condition>Systemic Lupus Erythematosus</condition>
  <arm_group>
    <arm_group_label>Recombinant Human Interleukin-2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Induced remission period,recombinant human IL-2(500,000 unit per square meter) infusions five days;Maintenance treatment period,recombinant human IL-2 infusions five days then once every two weeks for 6 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Traditional therapy</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients were treated with glucocorticoid and/or immunosuppressor.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IL-2</intervention_name>
    <description>Patients were received low dose recombinant human Interleukin-2</description>
    <arm_group_label>Recombinant Human Interleukin-2</arm_group_label>
    <other_name>Recombinant Human Interleukin-2 for Injection</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. age &lt;18 years old

          2. meet the diagnostic criteria of disease classification

          3. HIV negative;Negative for Hepatitis B Virus and Hepatitis C Virus.

        Exclusion Criteria:

          1. heart failure (cardiac function ≥ grade III NYHA)

          2. liver insufficiency (upper limit of normal range of transaminase &gt; 2 times)

          3. renal insufficiency (creatinine clearance ≤30ml/min)

          4. acute or severe infections such as bacteremia and sepsis

          5. malignant tumor

          6. high-dose steroid pulse therapy or intravenous injection of glucocorticoids in the
             last 1 month;Rituximab, infliximab or other biological agents were used

          7. mental disorders or any other chronic illness or substance abuse may interfere with
             the ability to comply with agreements or provide information

          8. Inability to comply with IL-2 treatment regimen.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yang si rui, MD and PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>First Hospital of Jilin University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yang si rui, MD and PhD</last_name>
    <phone>13500889222</phone>
    <email>sryang@jlu.edu.cn</email>
  </overall_contact>
  <reference>
    <citation>Rosenzwajg M, Lorenzon R, Cacoub P, Pham HP, Pitoiset F, El Soufi K, RIbet C, Bernard C, Aractingi S, Banneville B, Beaugerie L, Berenbaum F, Champey J, Chazouilleres O, Corpechot C, Fautrel B, Mekinian A, Regnier E, Saadoun D, Salem JE, Sellam J, Seksik P, Daguenel-Nguyen A, Doppler V, Mariau J, Vicaut E, Klatzmann D. Immunological and clinical effects of low-dose interleukin-2 across 11 autoimmune diseases in a single, open clinical trial. Ann Rheum Dis. 2019 Feb;78(2):209-217. doi: 10.1136/annrheumdis-2018-214229. Epub 2018 Nov 24.</citation>
    <PMID>30472651</PMID>
  </reference>
  <reference>
    <citation>Fontenot JD, Rasmussen JP, Gavin MA, Rudensky AY. A function for interleukin 2 in Foxp3-expressing regulatory T cells. Nat Immunol. 2005 Nov;6(11):1142-51. Epub 2005 Oct 16. Erratum in: Nat Immunol. 2006 Apr;7(4):427.</citation>
    <PMID>16227984</PMID>
  </reference>
  <reference>
    <citation>Malek TR. The biology of interleukin-2. Annu Rev Immunol. 2008;26:453-79. Review.</citation>
    <PMID>18062768</PMID>
  </reference>
  <reference>
    <citation>Cheng G, Yu A, Malek TR. T-cell tolerance and the multi-functional role of IL-2R signaling in T-regulatory cells. Immunol Rev. 2011 May;241(1):63-76. doi: 10.1111/j.1600-065X.2011.01004.x. Review.</citation>
    <PMID>21488890</PMID>
  </reference>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>May 6, 2020</study_first_submitted>
  <study_first_submitted_qc>May 19, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 21, 2020</study_first_posted>
  <last_update_submitted>July 22, 2020</last_update_submitted>
  <last_update_submitted_qc>July 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rheumatic Diseases</mesh_term>
    <mesh_term>Lupus Erythematosus, Systemic</mesh_term>
    <mesh_term>Collagen Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aldesleukin</mesh_term>
    <mesh_term>Interleukin-2</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

